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Abstract
Background: Whether diabetes mellitus (DM) is a predictor of long-term adverse clinical outcomes after repeat drug
eluting stent (DES) implantation for DES in-stent restenosis (ISR) remains controversial. We sought to evaluate the effect
of DM on the long-term clinical outcomes in patients undergoing repeat DES implantation for DES-ISR lesions.
Methods: In the present study, 254 patients with DES-ISR were divided into DM or non-DM groups according to the
presence or absence of DM. All patients received repeat 2nd generation DES implantation for DES-ISR. The occurrences of
major adverse cardiac events (MACEs) over a 2-year follow-up period were compared between the two groups. MACEs
were defined as cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR). MACE free survival was
investigated with Kaplan-Meier curve analysis. Cox regression analysis was used to identify factors associated with MACEs.
Results: Baseline clinical characteristics were similar between groups, except for the prevalence of early restenosis
(lower) in the DM group. Differences in angiographic and procedural characteristics were not significant between
groups. The rates of 2-year MACE (30.9 vs. 26.0%; P = 0.453) and TLR (24.7 vs. 19.7%; P = 0.411) were similar between
groups. MACE-free survival and TLR-free survival were also similar between groups (P = 0.441 and P = 0.807). Subgroup
analysis suggested a significant difference in the MACE (39.0 vs.15.3%, P < 0.001) and TLR occurrence (30.5 vs.8.2%,
P < 0.001) and TLR-free survival (lower in early subgroup, P < 0.001) between early and late occurrence of ISR in the
non-DM group of patients but not in the DM group. After adjustment for all significant clinical variables, Cox regression
analysis indicated that DM was not associated with MACEs (hazard ratio [HR] 1.531, 95% confidence interval [CI] 0.882-2.
658, P =0.130). Non-focal type ISR and early ISR were predictors of MACEs (HR 2.671, 95% CI 1.468-4.858,P = 0.001; HR 4.
703, 95% CI 2.725-8.117, P < 0.001, respectively).
Conclusions: Patients with DM have similar 2-year clinical outcomes to patients without DM when repeat 2nd generation
DES was used for treatment of DES-ISR. DM is not the predictor of long-term prognosis in patients undergoing repeat 2nd
generation DES for DES-ISR.
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Background
Drug eluting stents (DES) widely used in clinical practice
have dramatically reduced subsequent repeat target lesion
revascularizations (TLR) after percutaneous coronary
intervention (PCI) [1, 2]. Nevertheless, it is far away from
completely eliminating in stent restenosis (ISR). Current
therapeutic strategies to address ISR include plain balloon
angioplasty, cutting balloon angioplasty, repeat DES
implantation, radiation therapy, and drug coated balloon
(DCB) angioplasty. Among these strategies, repeat DES
implantation and DCB angioplasty are the most effective
methods for treatment of ISR [3]. Repeat DES implant-
ation is the most preferred modality because DCB is not
available in our hospital.
Diabetes mellitus (DM) has been an established pre-
dictor of TLR and major adverse cardiac events (MACEs)
after PCI for coronary de novo lesions [4, 5]. The biologic
effects of DM include leading to plaque growth, vascular
instability and risk of thrombosis [4]. However, in DES era
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some studies have suggested that DM has no longer corre-
lated with ISR [6, 7], while others still identify DM as a
predictor of TLR [8]. Overall it is likely that DM is not a
predictor of ISR for vein grafts and simple lesions (ACC/
AHA type A/B1 lesions) and unprotected left main coron-
ary artery lesions [5, 9, 10].
In the 2nd generation DES era, whether DM remains a
predictor of long-term adverse clinical outcomes after
repeat DES implantation for DES-ISR is controversial
[6–8]. Resolving this question would help cardiologists
choose the optimal therapy for these patients.
In order to evaluate the effect of DM on the long-term
clinical outcomes in a consecutive series of patients under-
going repeat DES implantation for DES-ISR lesions, we
compared 2-year MACEs between patients with DM and
patients without DM from our PCI registry. The aim of this
study was to discover whether DM is a predictor for
MACEs in patients undergoing repeat DES after DES-ISR.
Methods
Patients
This study was a retrospective analysis of prospectively en-
rolled patients. The study population included 254 con-
secutively enrolled patients treated between January 2011
and March 2013 from the department of Cardiology,
Beijing Anzhen Hospital, Capital Medical University’s PCI
registry with previous PCI undergoing repeat DES implant-
ation for ISR. Written informed consent was obtained from
all patients. The institutional review boards at Beijing
Anzhen Hospital and Research Institute of heart, lung and
vascular disease (Beijing, China) approved this study.
Patients with the following criteria were included in this
study. Patients with ISR defined as more than 50% diameter
stenosis quantified by quantitative coronary angiography
(QCA) in addition to myocardial ischemia and restenosis of
a DES implanted for a de novo lesion. Myocardial ischemia
was evaluated based on patients’ symptoms or noninvasive
tests (stress electrocardiography and stress myocardial scin-
tigraphy). Careful evaluation was performed by the clinical
staff for the requirement to undergo repeat DES. Patients
with the following conditions were excluded: Recurrent re-
stenosis meaning lesions in graft vessels that were not ISR,
thrombotic lesions suggested by angiographic findings.
Study design
According to the presence or absence of DM all patients
were divided into 2 groups (DM group and non-DM
group). DM was defined as either a previous diagnosis of
DM from the patient’s clinical history that had been
treated with diet, oral agents, peptide analogs or insulin,
or a new diagnosis during hospitalization according to the
World Health Organization guidelines of fasting plasma
glucose ≥ 7.0 mmol/l (126 mg/dl) or 2–h plasma glucose ≥
11.1 mmol/l (200 mg/dl) [11].
Either everolimus-eluting stents (EES, Xience V; Abbott
Vascular, Santa Clara, California, USA) or zotarolimus-
eluting stents (ZES, Resolute; Medtronic Inc., Santa Rosa,
California, USA) were implanted for treatment of ISR
lesions.
A radial or a femoral approach was used for PCI using a
6 Fr or larger guide catheter to facilitate subsequent QCA.
No bias was introduced in the choice of interventional ap-
proaches and DES. All patients provided informed consent
for undergoing the procedure. For each case, the interven-
tional physician remains the same with over ten years’ ex-
perience of PCI. Aspirin (300-mg loading-dose followed by
100 mg/day) was taken immediately after diagnosis with
initial stenosis and thereafter. After PCI, patients received
antiplatelet therapy with clopidogrel (75 mg/day following
loading dose of 300 mg) for at least 1 year.
QCA was performed using an automatic edge-detection
system (GE Co., California, USA). Coronary angiograms
were analyzed at the angiographic core laboratory by
trained personnel blinded to the group allocation. QCA
measurements were obtained on both an in-stent basis
(confined to the stented region) and an in-segment basis
(including the vessel 5 mm proximal and distal to the
stent). Lesion morphology was evaluated following The
American College of Cardiology/American Heart Associ-
ation (ACC/AHA) classification. Lesion length was mea-
sured from QCA measurements before PCI. Calcification
was assessed by coronary angiography and qualitatively
classified as none, mild, moderate, or severe. Angulation
was quantified by measuring the maximal angle in the
target lesion before PCI. The vessel angulation was classi-
fied as minor (<45°), moderate (45–90°), and severe (>90°).
Ostial lesions were within 3 mm of the coronary ostium
or 3 mm distal to a major proximal side branch. A
diameter of stenosis greater than 50% involving the main
parent vessel, with or without involvement of side branch
ostium, or the origin of the side branch was defined as
bifurcation lesion. We classified the types of restenosis
into focal type (<10 mm in length) and non-focal type,
which included diffuse (restenosis > 10 mm within the
stent), proliferative (restenosis >10 mm in length extend-
ing outside the stent), and occlusive. At the same time,
they were also classified into early type (found any time in
1 year after DES implantation) and late type (found any
time after 1 year after DES implantation).
Clinical data collection
A dedicated data coordinating center performed all data
management and analyses. Pre-specified clinical and demo-
graphic data, as well as clinical events during hospitalization,
were collected from the hospital charts, reviewed by quali-
fied personnel blinded to the objectives of the study, and
entered prospectively into the database. Long-term clinical
outcomes were conducted by clinic visit.
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Data was collected for the occurrence of MACEs, de-
fined as the combined incidence of death, MI, and TLR
[12]. Death was defined as mortality from cardiac cause.
MI was defined as typical ischemic chest pain and/or ST-
segment and/or T-wave abnormalities with a creatine kin-
ase isoenzyme-MB increase 2 times the reference values.
We defined TLR as clinically driven revascularization of
index lesion. A residual stenosis of <30% with TIMI-3 flow
was defined as PCI angiographic success. Angiographic
success without TLR, Q wave MI, or death prior to hos-
pital discharge was defined as clinical success. We defined
Chronic renal insufficiency (CRI) as patients receiving
medical therapy or dialysis for chronic renal failure or
have a creatinine level 2.0 mg/dL on admission.
Statistical analysis
All statistical analyses were performed using the SPSS
statistical software package (version 17.0; SPSS Inc.,
Chicago, Illinois, USA). A normality test demonstrated a
normal distribution of the data. We presented continu-
ous variables as mean ± SD while categorical variables as
frequencies (%). Unpaired Student’s t-test was used for
comparison of continuous variables and categorical vari-
ables was compared using χ2 or Fisher’s exact tests. A
Kaplan–Meier curve was plotted for the MACE-free sur-
vival of both groups using GraphPad Prism (version 5;
GraphPad Software Inc., La Jolla, California, USA).
Difference between groups was evaluated by a log-rank
test. A censored data indicated the loss of follow up. A
Cox regression analysis was performed to identify
whether there is independent association between DM
and higher incidence of MACEs. Variables were selected
on the basis of overall clinical relevance, according to
the previously published literature with particular atten-
tion paid to clinical and procedural factors that would
make MACE more likely and included age, sex, hyper-
tension, diabetes mellitus, chronic renal insufficiency,
calcification lesion, bifurcation lesions, no-focal lesion
and early restenosis. Statistical significance was defined
as a P value less than 0.05.







Age (years) 60.22 ± 10.36 59.42 ± 10.68 0.572
Male (%) 65 (80.2%) 136 (78.6%) 0.869
Smoking (%) 20 (24.7%) 44 (25.4%) 0.950
Prior diseases
Hyperlipidemia (%) 38 (46.9%) 87 (50.3%) 0.687
Previous MI (%) 7 (8.6%) 22 (12.7%) 0.402
Hypertension (%) 37 (45.7%) 77 (44.5%) 0.632
Chronic renal insufficiency (%) 12 (14.8%) 25 (14.5%) 0.873
Clinical presentation
Stable angina (%) 52 (64.2%) 99 (57.2%) 0.646
Unstable angina (%) 21 (25.9%) 48 (27.7%)
NSTEMI (%) 5 (6.2%) 15 (8.7%)
STEMI (%) 3 (3.7%) 11 (6.4%)
Medication
ACEI/ARB (%) 53 (65.4%) 119 (68.8%) 0.666
Dural antiplatelet therapy (%) 73 (90.1%) 149 (86.1%) 0.423
Statin therapy (%) 75 (92.6%) 151 (87.3%) 0.283
Lab parameters
Fasting glucose 7.647 ± 2.416 5.586 ± 1.189 <0.001
Hemoglobin A1c 7.373 ± 1.216 5.463 ± 0.754 <0.001
Type of restenosis
Early restenosis 27 (24.8%) 82 (48.2%) 0.04
Non-focal restenosis (%) 23 (28.4%) 64 (37%) 0.203
Data are presented as mean ± SD or n (%)
MI myocardial infarction, NSTEMI non-ST segment elevated myocardial
infarction, STEMI ST segment elevated myocardial infarction, ACEI
angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker







LM/LAD/LCX/RCA 2/38/14/27 4/97/29/43 0.498
Type B2/C lesions 68 (84%) 133 (76.9%) 0.196
Lesions
Lesion lengths, mm 25.81 ± 10.82 23.86 ± 11.02 0.187
Ostial location 9 (11.1%) 18 (10.4%) 0.865
Angulation > 45° 34 (42%) 58 (33.5%) 0.209
Moderate-severe calcification 16 (19.8%) 30 (17.3%) 0.727
Bifurcation 19 (23.5%) 49 (28.5%) 0.449
Repeat DES
Type (EES/ZES) 37/44 69/104 0.414
Number of stents (n) 1.61 ± 0.92 1.75 ± 0.89 0.263
Stent length (mm) 27.21 ± 10.92 24.65 ± 10.83 0.082
Stent diameter (mm) 2.86 ± 0.41 2.93 ± 0.39 0.234
Data are presented as mean ± SD or n (%)
LM left main coronary artery, LAD left anterior descending coronary artery, LCX
left circumflex artery coronary artery, RCA right coronary artery, EES Everolimus
Eluting Stent, ZES Zotarolimus Eluting Stent






MACE 25 (30.9%) 45 (26%) 0.453
TLR 20 (24.7%) 34 (19.7%) 0.411
MI 3 (3.7%) 8 (4.6%) 0.996
Death 2 (2.5%) 3 (1.7%) 0.655
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Results
Baseline clinical characteristics
Among the 254 consecutive patients, 81 patients were
diagnosed with DM. The baseline clinical characteristics
of the patients are listed in Table 1. There were no signifi-
cant differences in many coronary artery disease risk fac-
tors including hyperlipidemia, and smoking between the
two groups. In the DM group, the mean hemoglobin A1c
(HbA1c) and mean fasting plasma glucose level were
higher than those in the non-DM group (HbA1c, 7.373 ±
1.216 vs. 5.463 ± 0.754%, P < 0.001, fasting glucose, 7.647
± 2.416 vs. 5.586 ± 1.189, P < 0.001). Fewer cases of early
restenosis occurred in the DM group than the non-DM
group (24.8 vs.48.2%, P = 0.04).
Angiographic and procedure characteristics
All procedures were successful, both angiographically and
clinically, without any major complications. All patients
were discharged home after the intervention at a mean
duration of 2.3 ± 1.6 days. The angiographic and proced-
ural characteristics are displayed in Table 2. The lesion-
based angiographic and procedural characteristics were
similar between the both groups with no significant
differences.
2-year clinical outcome
During the 2-year follow-up period, total 4 patients in DM
group and 9 patients in non-DM group were lost to
follow-up. As shown in Table 3, 25 MACEs were observed
in the DM group and 45 in the non-DM group (30.9 vs.
26.0%; P = 0.453). TLR was required in 20 patients in the
DM group and 34 in the non-DM group (24.7 vs. 19.7%;
P = 0.411). Two patients in the DM group and 3 patients
in the non-DM group died from all-cause mortality (2.5
vs.1.7%, P = 0.655). Three patients in the DM group
and 8 patients in the non-DM group had MI (3.7 vs.4.6%,
P = 0.996). The Kaplan–Meier curves showed that the DM
group had similar MACE-free survival to the non-DM
group with the log-rank test (P =0.441, Fig. 1a) and similar
TLR-free survival (P = 0.807, Fig. 1b).
Analysis of MACEs according to early- or late-ISR
When stratification analysis was performed according to
the occurrence of early-ISR or late-ISR in the two groups it
became apparent that there was no significant difference in
the occurrence of MACEs between early and late ISR sub-
groups in the DM group but in the non-DM group there
was a significantly higher rate of overall MACEs and TLR
in the early ISR subgroup than in the late ISR subgroup
(both P < 0.001, Table 4), but rates of MI and death were
similar. Kaplan-Meier curves supported this within the DM
subgroups with similar TLR-free survival (P =0.804, Fig. 2a)
and a significant difference was found between the non-
DM subgroups for TLR-free survival (P < 0.001, Fig. 2b).
Factors that predict MACEs
Parameters used in the multivariable model to assess the
predictors of 2-year MACEs included age, sex, hypertension,
DM, chronic renal insufficiency, calcification lesion, bifur-
cation lesions, no-focal lesion and early restenosis. Cox re-
gression result showed that non-focal lesion (hazard ratio
(HR) 2.671, 95% confidence interval (CI) 1.468–4.858, P
=0.001) and early restenosis (HR 4.703, 95%CI 2.725-8.117,
P < 0.001) were independent predictors of MACEs among
the nine variables included in the current study (Table 5).
Discussion
The results reveal that there were no differences in the
rate of 2-year MACEs in DM and non-DM groups in
our study population (30.9% in DM group vs. 26% in
non-DM group, P = 0.453).It indicates that DM is not a
risk factor of poor long-term prognosis in patients
undergoing repeat 2nd generation DES implantation for
DES-ISR (HR 1.531, 95%CI 0.882-2.658, P = 0.130).
Clinical use of DES has reduced the incidence of ISR, but
treatment of DES-ISR is still challenging. [3, 13] The
etiology of ISR remains unclear. Smooth muscle cell prolif-
eration and neoatherosclerosis are the probable causes [14].
Clinical studies have proved that repeat DES implantation
could acquire acceptable clinical and angiographic results
for DES-ISR treatment [8–18]. Intravascular ultrasound
Fig. 1 Kaplan–Meier curves of 2-year MACE-free and TLR-free survival
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(IVUS) or optical coherence tomography (OCT) can give us
more important details of lesion characteristics of DES-ISR,
which may improve the clinical results of repeat DES for
DES-ISR treatment [19, 20]. Unfortunately, IVUS or OCT
was not used for every patient enrolled in our study. During
the 2-year follow-up of our study, 25 MACEs including 20
TLR were observed in the DM group and 45 MACEs in-
cluding 34 TLR in the non-DM group. More TLRs occurred
in the current study than previous studies [15–18]. In
current study, follow-up period was 2 years which is
relatively longer than that in previous studies [17, 18], which
indicated that a longer follow-up period may contribute to
the higher occurrence of TLR than before [14]. In addition,
multivariable model analysis showed that non-focal and
early ISR were the only two independent predictors of
MACEs over the 2-year follow-up. Therefore, the angio-
graphic type of DES-ISR, especially the non-focal type, and
early phase of DES-ISR were highly associated with the TLR
after repeat DES implantation. When our data was analyzed
in terms of early and late occurrence of ISR we found that
the differences in the rate of MACEs and TLR and TLR-
free survival were significant only in the non-DM group. It
is not clear why the occurrence of early ISR was not import-
ant for MACEs and in particular TLR in the DM group, but
the DM subgroups were smaller than the non-DM sub-
groups so this may have influenced the analysis. Further
studies are needed to investigate the mechanisms and better
treatment methods for non-focal and early phase DES-ISR
and whether these are influenced by DM.
It is well known that DM is a risk factor for MACE after
PCI, but whether DM is still an independent predictor of
ISR after PCI for all lesions is unknown in the DES era, es-
pecially in the 2nd generation DES era. Previous studies
have reported conflicting results [6–8]. Some of them com-
paring outcomes after PCI with 2nd DES suggest that DM
no longer correlates with ISR [6, 7], whereas others confirm
that DM is still a risk factor of TLR [8]. Therefore, some in-
vestigators have concluded that DM is no longer a pre-
dictor of ISR after DES implantation for specific
populations, such as patients with vein graft lesions, simple
lesions (ACC/AHA type A/B1 lesions) and unprotected left
main [5, 9, 10]. This study suggests that in 2nd generation
DES era, DM is not an independent risk factor of MACE in
patients accepting repeat DES implantation for DES-ISR.
The 2nd generation DES is better in reducing ISR than the
1st generation DES and BMS, which correlates with similar
2-year rates of TLR and overall MACE between DM and
non-DM patients with ISR lesions in this study. On the
other hand, ISR lesions are different from coronary de novo
lesions [21], which maybe in part contribute to these results
in these special patients. At the same time, our study re-
veals that non-focal type and early ISR independently pre-
dict the adverse outcomes after PCI for DES-ISR with 2nd
generation DES, which indicates that mechanical factors
underlying non-focal type or early ISR other than DM
maybe play important roles in the repeat occurrence of ISR
after PCI for DES-ISR lesions [22–24].
Limitation
Our study is a real-world, single-center, retrospective
study about treatment of DES-ISR using 2nd generation
DES in DM patients. This study has some limitations.
First, it is a retrospective study and biases inherent in
this study may have substantially influenced the outcome
of the results. However, in general, the groups were well
balanced in baseline clinical, angiographic, and proced-
ural characteristics. Other limitations of the present
study include a small sample size in particular in the
DM group, low use of OCT or IVUS in the total





R n = 27 n = 54 P-value n = 82 n = 85 P-value
Events
MACE 8 (30.9%) 17 (26%) 0.712 32 (39.0%) 13 (15.3%) <0.001
TLR 7 (25.9%) 15 (27.8%) 0.997 25 (30.5%) 7 (8.2%) <0.001
MI 1 (3.7%) 1 (1.9%) 0.998 5 (6.1%) 4 (4.7%) 0.743
Death 0 (0.0%) 1 (1.9%) 0.817 2 (2.4%) 2 (2.4%) 0.971
Fig. 2 Kaplan–Meier curves of 2-year TLR-free survival in the early and late ISR subgroups. a: DM-ISR KM curve; b: Non DM-ISR KM curve
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population, lack of routine angiographic follow-up, and
no information on the selection of DES for the previous
PCI because data was not available for patients treated
at other hospitals for their first intervention. However,
we did not find any significant differences between
groups with regard to TLR, death and MI. In view of
these limitations, our findings should be considered as a
primary hypothesis generating data for larger studies
that are needed to confirm the present findings.
Conclusions
Long term outcomes equate between DM and non-DM
groups of patients when a 2nd generation DES was used
for treatment of DES-ISR. DM is not a predictor of
long-term prognosis in patients undergoing repeat 2nd
generation DES for DES-ISR.
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